Ligand Pharmaceuticals LGND Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $174.93M+142% | $72.31M+215% | $22.95M-49.0% | $45.01M+131% | ||
| $558.59M+204% | $183.86M+24.8% | $147.36M-11.7% | $166.86M-48.1% | ||
| $59.6M+55.3% | $38.38M+16.6% | $32.92M+8.2% | $30.42M-64.4% | ||
| $9.13M-35.3% | $14.11M-41.1% | $23.97M+80.3% | $13.29M-51.4% | ||
| $832.27M+151% | $331.56M+39.6% | $237.43M-9.9% | $263.6M-43.3% | ||
| $3.57M-76.4% | $15.13M-3.0% | $15.61M+25.0% | $12.48M-5.4% | ||
| $101.54M-3.5% | $105.25M+1.8% | $103.37M— | $0-100% | ||
| $225.44M-15.5% | $266.65M-11.0% | $299.61M-12.5% | $342.46M-9.1% | ||
| $1.56B+65.7% | $941.77M+19.6% | $787.22M+3.2% | $762.67M-41.2% | ||
| $3.24M-38.1% | $5.23M+116% | $2.43M-54.3% | $5.31M-36.8% | ||
| $621K0.0% | $621K-49.2% | $1.22M+244% | $355K-45.7% | ||
| $37.45M+0.9% | $37.11M+121% | $16.78M-83.0% | $98.81M+137% | ||
| $3.22M-97.1% | $111.34M+29.0% | $86.3M-47.8% | $165.18M-65.3% | ||
| 60M+299,900% | 20K+11.1% | 18K+5.9% | 17K0.0% | ||
| $608.09M+21.9% | $498.98M-0.8% | $503.02M+11.6% | $450.86M+0.4% | ||
| $1.02B+22.5% | $830.44M+18.5% | $700.91M+17.3% | $597.49M-27.2% | ||
| $1.56B+65.7% | $941.77M+19.6% | $787.22M+3.2% | $762.67M-41.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Ligand Pharmaceuticals cover its short-term obligations?
- Its current ratio is 21.28 — current assets exceed current liabilities.
- Where does Ligand Pharmaceuticals's balance sheet data come from?
- Every line is extracted from Ligand Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.